Spike RBD triple mutant (K417N, E484K and N501Y) SARS-CoV-2(2019nCoV) Pseudotyped virus production and Pseudovirus Based Neutralization Assay

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage

The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV)lineage (501Y.V2,B.1.351), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces of South Africa.

Mutations of Spike protein in SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) (B.1.351) spread in South Africa

Three of the spike mutations are at key residues in the RBD (N501Y, E484K and K417N), three are in the N-terminal domain (L18F, D80A and D215G) and one is in loop 2 (A701V). Deletion of three amino acids at L242-244L is disputed with a L242H mutation¹.

Figure. Amino acid changes in the spike region of the 190 S501Y.V2 genomes¹

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage